The U.S. Food and Drug Administration announced it has conditionally approved Varenzin-CA1, the first drug for the control of nonregenerative anemia associated with chronic kidney disease, or CKD, in cats. The FDA granted conditional approval of Varenzin-CA1 to Elanco US Inc. Reference Link
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ELAN: